AstraZeneca

At AstraZeneca, we are committed to driving healthcare system transformation to improve outcomes for patients living with amyloidosis around the world. The launch of the global Accelerate Change Together (ACT) on Amyloidosis programme demonstrates our dedication to working with the broader healthcare community to achieve shared goals and transform amyloidosis care.

We are deeply committed to transforming respiratory care. As leaders in respiratory for more than five decades, we continue to drive innovation that benefits patients, society and the planet, affirmed by our presence at this year’s European Respiratory Society Congress.

In emerging markets, where the burden of noncommunicable diseases (NCDs) is highest and patient outcomes are greatly affected by healthcare inequality, artificial intelligence (AI) is increasingly offering scalable, affordable, and impactful solutions.

At AstraZeneca we harness data and technology to maximise time for the discovery and delivery of potential new medicines. Data science and artificial intelligence (AI) are embedded across our R&D to enable our scientists to push the boundaries of science to deliver life-changing medicines.

From lab to patient, our focus on sustainable science is helping us to deliver better health outcomes with a lower environmental footprint.

Approval of first-in-class, oral, Factor D inhibitor based on ALPHA Phase III trial in a subset of patients with PNH.